Phase 3 Type 1 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with type 1 diabetes for at least 1 year before the screening visit.
- People who have been using a daily long-acting insulin injection plus a fast-acting insulin injection regimen for at least 6 months before the screening visit.
- People whose HbA1c (a blood test that shows average blood sugar levels over roughly 3 months) falls between 7.0% and 10.0%, confirmed by a central laboratory at screening.
- People who are willing and able to follow the study requirements, including regularly checking and recording their own blood sugar levels, as assessed by the study doctor.
Who may not be able to join:
- People with a known or suspected allergy or sensitivity to the study treatment or closely related products.
- People who have previously signed a consent form to participate in this same study.
- People who are pregnant, breastfeeding, planning to become pregnant, or who are able to become pregnant and are not using an appropriate method of contraception.
- People who have taken part in another clinical trial involving an experimental medicine within 90 days (or longer, depending on how long that medicine stays in the body) before screening.
- People who have any other health condition — unrelated to type 1 diabetes — that the study doctor believes could affect their safety or ability to follow the study requirements.
- People who are expected to start or change a medication (for more than 15 days in a row) that is known to affect weight or blood sugar levels, such as thyroid hormones or steroid medications.
- People who have difficulty recognising the warning signs of low blood sugar, as determined by the study doctor using a standard questionnaire.
- People who have had repeated serious low blood sugar episodes in the past year, as assessed by the study doctor.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Phone: (+1) 866-867-7178
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change in glycosylated haemoglobin (HbA1c)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.